Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.

By C. Regillo, David M. Brown, P. Abraham, H. Yue, T. Ianchulev, S. Schneider, Naveed B. K. Shams. American journal of ophthalmology-glaucoma, 2008

888 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. (2014, neutral): “To reduce the treatment burden and still conform to a structured regimen, treatment intervals were expanded in studies such as the Phase IIIB, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Patients with AMDRelated Subfoveal Choro”
Digital technology, tele-medicine and artificial intelligence in ophthalmology: A global perspective (2020, background): “Although several efforts have made to reduce the clinical burden by modifying injection protocols, such as ‘treat and extend ’ (Gupta et al., 2010; Regillo et al., 2008), the number of patient visits by AMD patients continue to increase due to the growth of the aged population and the chronic and…”
Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Results from the Phase IIIb PIER 211 and It was not until the 1990s that multiple lines of evidence converged on VEGFA as the sought after factor X. VEGFA is produced in human and non-human primate retina 186,187 , and its levels increase when the retina becomes ischaemic 187 .”